{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:19:26Z","timestamp":1699892366683},"reference-count":67,"publisher":"Hindawi Limited","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2945,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01514.x","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T15:57:54Z","timestamp":1186675074000},"page":"1914-1921","source":"Crossref","is-referenced-by-count":9,"title":["Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan\u00ae)"],"prefix":"10.1155","volume":"61","author":[{"given":"A.","family":"Vogt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Hostalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2007,8,9]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB1|cit1","unstructured":"National Cholesterol Education Program Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) National Institutes of Health\/National Heart Lung and Blood Institute http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1093\/eurheartj\/sui040","article-title":"The realities of dyslipidaemia: what do the studies tell us?","volume":"7","author":"Kastelein","year":"2005","journal-title":"Eur Heart J Suppl"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2007.01514.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc07-S004","article-title":"Standards of medical care in diabetes - 2007","volume":"30","author":"American Diabetes Association","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB5|cit5","unstructured":"Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Guidelines on Diabetes, Pre-diabetes and Cardiovascular Diseases: Full Text http:\/\/www.escardio.org"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB6|cit6","unstructured":"Clinical Guidelines Task Force of the International Diabetes Federation Global Guideline for Type 2 Diabetes (2005) http:\/\/www.idf.org"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/eurheartj\/ehl220","article-title":"Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The Framingham Heart Study","volume":"8","author":"Wilson","year":"1988","journal-title":"Arteriosclerosis"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl.","key":"10.1111\/j.1742-1241.2007.01514.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1185\/030079905X74871","article-title":"High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients","volume":"21","author":"Bruckert","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","article-title":"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C","volume":"20","author":"Chapman","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jacc.2003.08.061","article-title":"Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update","volume":"43","author":"Gotto","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night vs. plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"1","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial","volume":"1","author":"Morgan","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"24U","DOI":"10.1016\/S0002-9149(98)00847-9","article-title":"Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing","volume":"82","author":"Knopp","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"F68","DOI":"10.1093\/eurheartj\/sul044","article-title":"Achieving the therapeutic benefits of Niaspan in daily practice","volume":"8","author":"Reasner","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB37|cit37","first-page":"278","article-title":"Safety and tolerability of prolonged-release nicotinic acid in patients aged \u2265\u200365\u2003years enrolled in NAUTILUS","volume":"13","author":"Vogt","year":"2006","journal-title":"Br J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB38|cit38","first-page":"273","article-title":"Safety and tolerability of prolonged-release nicotinic acid combined with a statin in NAUTILUS","volume":"13","author":"Vogt","year":"2006","journal-title":"Br J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/14746514060060030501","article-title":"NAUTILUS (safety and tolerability of Niaspan\u00ae): a subgroup analysis of patients with diabetes","volume":"6","author":"Vogt","year":"2006","journal-title":"Br J Diabetes Vasc Dis"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB41|cit41","unstructured":"Grundy SM Vega GL McGovern ME et\u00a0al Comparative effects on lipids and glycemic control of niacin extended-release\/lovastatin or fenofibrate in patients with diabetic dyslipidemia Abstract 29-LB, Presented at the 64th Scientific Sessions of the American Diabetes Association, 4-8 June 2004, Orlando, FL, USA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB42|cit42","article-title":"Once-daily niacin-extended-release\/lovastatin combination is effective and safe for treatment of dyslipidaemia associated with metabolic syndrome","author":"McGovern","journal-title":"Abstract 820-5, 2004 Scientific Session of the American College of Cardiology."},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cll.2006.07.002","article-title":"Lipoprotein(a): a unique risk factor for cardiovascular disease","volume":"26","author":"Anuurad","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0002-9149(03)00394-1","article-title":"Effects of extended-release niacin on lipoprotein subclass distribution","volume":"91","author":"Morgan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1520-037X.2003.03142.x","article-title":"Once-daily niacin extended release\/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin","volume":"6","author":"Bays","year":"2003","journal-title":"Prev Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0002-9149(02)02333-0","article-title":"Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus","volume":"89","author":"Van","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","article-title":"Efficacy of extended-release niacin with lovastatin for hypercholesterolemia assessing all reasonable doses with innovative surface graph analysis","volume":"164","author":"Insull","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/clc.4960260304","article-title":"A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin","volume":"26","author":"Hunninghake","year":"2003","journal-title":"Clin Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor vs. Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9149(00)01410-7","article-title":"Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia","volume":"87","author":"Wolfe","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"82U","DOI":"10.1016\/S0002-9149(98)00955-2","article-title":"Treatment of hyperlipidemia with combined niacin-statin regimens","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24\u2003months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB55|cit55","unstructured":"AIM-HIGH trial http:\/\/www.clinicaltrials.gov"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2005.01.073","article-title":"Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia","volume":"95","author":"Vega","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","article-title":"Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis","volume":"292","author":"Psaty","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB61|cit61","unstructured":"Al-Sheikh AA Karas RH Relative safety of lipid altering drugs in the general population Abstract 3707 at the 2005 American Heart Association Scientific Sessions, Dallas, TX, USA, 13-16 November 2005."},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00007611-199401000-00007","article-title":"Niacin-induced hepatotoxicity: unusual presentations","volume":"87","author":"Coppola","year":"1994","journal-title":"South Med J"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0002-9343(92)90689-9","article-title":"Hepatotoxicity associated with sustained-release niacin","volume":"93","author":"Dalton","year":"1992","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB64|cit64","first-page":"S308","article-title":"Understanding niacin formulations","volume":"8","author":"Pieper","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0889-8553(21)00233-8","article-title":"Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents","volume":"24","author":"Lahoti","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB133|cit66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1525-1497.1997.07118.x","article-title":"Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions","volume":"12","author":"Jungnickel","year":"1997","journal-title":"J Gen Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01514.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01514.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01514.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:08Z","timestamp":1643349908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01514.x"}},"subtitle":["Nicotinic acid for the correction of low HDL-C"],"short-title":[],"issued":{"date-parts":[[2007,8,9]]},"references-count":67,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01514.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8,9]]}}}